Erlmeier, Franziska and Bruecher, Benedict and Stoehr, Christine and Herrmann, Edwin and Polifka, Iris and Agaimy, Abbas and Trojan, Lutz and Stroebel, Philipp and Becker, Frank and Wuelfing, Christian and Barth, Peter and Stoeckle, Michael and Staehler, Michael and Stief, Christian and Haferkamp, Axel and Hohenfellner, Markus and Macher-Goeppinger, Stephan and Wullich, Bernd and Noldus, Joachim and Brenner, Walburgis and Roos, Frederik C. and Walter, Bernhard and Otto, Wolfgang and Burger, Maximilian and Schrader, Andres Jan and Hartmann, Arndt and Mondorf, Yvonne and Ivanyi, Philipp and Mikuteit, Marie and Steffens, Sandra (2022) cMET: a prognostic marker in papillary renal cell carcinoma? HUMAN PATHOLOGY, 121. pp. 1-10. ISSN 0046-8177, 1532-8392
Full text not available from this repository. (Request a copy)Abstract
The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PAN-ZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET(-) vs. cMET(+): pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET 2 [4.3%] vs. cMET(+): 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival. (C) 2021 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | C-MET; TYROSINE KINASE; CABOZANTINIB; IMMUNOSURVEILLANCE; OVEREXPRESSION; PROTOONCOGENE; ACTIVATION; EXPRESSION; EVEROLIMUS; MUTATIONS; cMET; Papillary renal cell carcinoma; Prognosis; Survival; Outcome |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Dec 2023 11:24 |
| Last Modified: | 12 Dec 2023 11:24 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58760 |
Actions (login required)
 |
View Item |
